Cargando…

Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma

BACKGROUND & OBJECTIVES: Inhibitors of immune checkpoint regulators, programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), improve outcome in advanced non-small-cell lung carcinoma (NSCLC). Tumours expressing PD-L1 protein are more likely to benefit from this targeted therapy. Multipl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nambirajan, Aruna, Husain, Nuzhat, Shukla, Saumya, Kumar, Sunil, Jain, Deepali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902360/ https://www.ncbi.nlm.nih.gov/pubmed/31823919 http://dx.doi.org/10.4103/ijmr.IJMR_367_18

Ejemplares similares

Programmed Death Ligand-1 Testing in Adenocarcinoma Lung: A Comparative Study of Cell Block versus Biopsy
por: Shukla, Saumya, et al.
Publicado: (2023)

Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype
por: Pandey, Rahul Kumar, et al.
Publicado: (2022)

Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples
por: Soo, Ross A., et al.
Publicado: (2018)

Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma
por: Phillips, Therese, et al.
Publicado: (2018)

Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non–small cell lung carcinoma
por: Nakra, Tripti, et al.
Publicado: (2021)

Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
por: Ahn, Soomin, et al.
Publicado: (2021)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Noske, Aurelia, et al.
Publicado: (2021)

Primary pulmonary epithelioid inflammatory myofibroblastic sarcoma: a rare entity and a literature review
por: Singh, Priyanka, et al.
Publicado: (2022)

Cytomorphological Features of Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Gene Rearrangement
por: Shukla, Saumya, et al.
Publicado: (2019)

Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
por: Mino-Kenudson, Mari
Publicado: (2016)

Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Harmonization across programmed death ligand 1 (PD‐L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing
por: Matsuo, Tsubasa, et al.
Publicado: (2021)

Increased Copy Number of Anaplastic Lymphoma Kinase Gene Signal in Lung Carcinomas: Is it Significant?
por: Shukla, Saumya, et al.
Publicado: (2019)

Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma
por: Parra, Edwin R., et al.
Publicado: (2018)

Mapping the immune landscape in small cell lung cancer by analysing expression of immuno-modulators in tissue biopsies and paired blood samples
por: Dutta, Rimlee, et al.
Publicado: (2023)

A Comparative Study of Cell Block versus Biopsy for Detection of Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangement in Adenocarcinoma Lung
por: Gupta, Vani, et al.
Publicado: (2019)

Scar Endometriosis: Cytological Diagnosis
por: Dwivedi, Urvashee, et al.
Publicado: (2018)

Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.
por: Henzen-Logmans, S. C., et al.
Publicado: (1992)

Immunohistochemistry of Programmed Cell Death in Archival Human Pathology Specimens
por: Hasui, Kazuhisa, et al.
Publicado: (2012)

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
por: Zajac, Magdalena, et al.
Publicado: (2019)

Controls for Immunohistochemistry: The Histochemical Society’s Standards of Practice for Validation of Immunohistochemical Assays
por: Hewitt, Stephen M., et al.
Publicado: (2014)

Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection
por: Holokai, Loryn, et al.
Publicado: (2019)

The utility of cytology in the diagnosis of adenocarcinoma lung: A tertiary care center study
por: Shukla, Saumya, et al.
Publicado: (2015)

Effects of Automation on Sustainability of Immunohistochemistry Laboratory
por: Đorđević, Marija, et al.
Publicado: (2021)

Introducing immunohistochemistry to the molecular biology laboratory
por: Chen, Audrey, et al.
Publicado: (2022)

Diagnostic Efficacy of BRAFV600E Immunocytochemistry in Thyroid Aspirates in Bethesda Category IV and Papillary Thyroid Carcinoma
por: Anand, Nidhi, et al.
Publicado: (2021)

Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays
por: Schwamborn, Kristina, et al.
Publicado: (2019)

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
por: Rebelatto, Marlon C., et al.
Publicado: (2016)

Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review
por: Sakakibara, Ayako, et al.
Publicado: (2021)

The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer
por: Lee, Yong Seok, et al.
Publicado: (2021)

Cell‐blocks are suitable material for programmed cell death ligand‐1 immunohistochemistry: Comparison of cell‐blocks and matched surgical resection specimens in lung cancer
por: Pak, Min Gyoung, et al.
Publicado: (2019)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Penile neurilemmoma: Utility of fine-needle aspiration cytology in diagnosis of a rare entity
por: Malhotra, Kiran Preet, et al.
Publicado: (2014)

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021)

On the Necessity of Validating Antibodies in the Immunohistochemistry Literature
por: Gautron, Laurent
Publicado: (2019)

Development of a LAG-3 immunohistochemistry assay for melanoma
por: Johnson, Lori, et al.
Publicado: (2023)

Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer
por: Baker, Gabrielle M, et al.
Publicado: (2015)

Analytic Validation of a Clinical-Grade PTEN Immunohistochemistry Assay in Prostate Cancer by Comparison to PTEN FISH
por: Lotan, Tamara L., et al.
Publicado: (2016)

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1
por: Cogswell, John, et al.
Publicado: (2016)

Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis
por: Şahin, Songül, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ob8to4lkife3vo3b7e3p771kj9